BEAT BioTherapeutics Corp. (BEATBio) is a Seattle, WA based biotechnology company founded to develop novel therapies for heart disease. BEAT Bio’s first product is based on a fundamental discovery in cardiac muscle contraction and the development of a novel GeneTherapy to improve cardiac performance in the setting of heart failure. BEATBio’s founding scientists have;
- Made a fundamental discovery that dATP increases contractility of heart muscle
- Developed a AAV-based gene therapy to express the rate-limiting enzyme for dATP synthesis (R1R2) and increase cardiac dATP levels
- Demonstrated that this gene therapy dramatically restores wall motion, ejection fraction and overall cardiac performance in animal models of heart failure
- Shown that a single administration lasts for life and that animals expressing the transgenes live normal life spans
- Observed that delivery to only a few cells enhances global function throughout the heart
- Shown that the beneficial effects of therapy do not deplete cardiac energy reserves or cause adverse changes in Ca2+ handling
- Restored contraction and relaxation properties to depressed cardiac muscle tissue from areas of injury
Treated hearts pump more blood under resting conditions and under increased cardiac workloads, restoring pumping function and improving the ability to supply oxygenated blood in Heart Failure.
BEATBio’s gene therapy represents a potentially transformational technology for the treatment of heart failure and myocardial infarctions.
BEATBio further couples these advances in cardiac gene therapy with tissue engineering, and cell therapy technology as part of our product development pipeline. Furthermore, BEATBio scientists possess superior capabilities in animal modeling of cardiac disease and cardiac performance assessment. Our founding scientists have developed analytical tools and molecular biology techniques for addressing fundamental questions about cardiac physiology and function, and technology development.
BEATBio’s technologies were developed at the University of Washington (UW) under a series of highly competitive NIH grants. BeatBio has obtained an exclusive, worldwide license to this suite of technologies.